Cite
HARVARD Citation
Schaefer, E. et al. (n.d.). Phase 1b/2 trial of taladegib (LY2940680), a Hh/Smo inhibitor, in combination with carboplatin and etoposide followed by taladegib maintenance in extensive-stage small-cell lung cancer. European journal of cancer. pp. S131-S132. [Online].